Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Notes Payables (2018 - 2025)

Historic Notes Payables for China SXT Pharmaceuticals (SXTC) over the last 7 years, with Q3 2025 value amounting to $976367.0.

  • China SXT Pharmaceuticals' Notes Payables rose 1793.04% to $976367.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $976367.0, marking a year-over-year increase of 1793.04%. This contributed to the annual value of $702184.0 for FY2025, which is 4241.52% up from last year.
  • China SXT Pharmaceuticals' Notes Payables amounted to $976367.0 in Q3 2025, which was up 1793.04% from $702184.0 recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Notes Payables ranged from a high of $976367.0 in Q3 2025 and a low of $24042.0 during Q3 2021
  • For the 4-year period, China SXT Pharmaceuticals' Notes Payables averaged around $436926.2, with its median value being $380162.0 (2023).
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Notes Payables plummeted by 4745.72% in 2021, and later soared by 20976.84% in 2024.
  • Over the past 4 years, China SXT Pharmaceuticals' Notes Payables (Quarter) stood at $24042.0 in 2021, then surged by 1011.68% to $267270.0 in 2023, then surged by 209.77% to $827918.0 in 2024, then increased by 17.93% to $976367.0 in 2025.
  • Its Notes Payables was $976367.0 in Q3 2025, compared to $702184.0 in Q1 2025 and $827918.0 in Q3 2024.